CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosisFelix Fischbach, Nicolaus Kröger, Dominic Borie et al.|Med|2024Cited by 161
Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course MonitoringDaniel Stoessel, Ole Pleß, Jan‐Patrick Stellmann et al.|Frontiers in Human Neuroscience|2018Cited by 67
CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple SclerosisJohanna Richter, Nicolaus Kroeger, Felix Fischbach et al.|Blood|2024Cited by 9
Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of lifeBente Braun, Vivien Häußler, Felix Fischbach et al.|Multiple Sclerosis and Related Disorders|2023Cited by 5
Autologous haematopoietic stem cell transplantation in multiple sclerosis: outcomes and predictors from German real-world dataFelix Fischbach, Christoph Heesen, Johanna Richter et al.|Journal of Neurology Neurosurgery & Psychiatry|2026Cited by 0